红霉素，[N-甲基-14C]（CAS 82343-12-2）：分子式 C37H67NO13、分子量 733.9。
| CAS号 | 82343-12-2 |
|---|---|
| 分子式 | C37H67NO13 |
| 分子量 | 733.9 |
| 熔点 | 133-135 |
| 沸点 | 719.69 |
| LogP | 2.6 |
| 应用领域 | Uses: Antibiotic、THERAPEUTIC CATEGORY: Antibacterial、Erythromycin stearate、THERAPEUTIC CATEGORY (VETERINARY): Antibacterial、MEDICATION、Use (kg) in Switzerland (2009): >100、Use (kg、approx.) in Germany (2009): >7500、exact) in Germany (2009): 9435、Use (kg) in USA (2002): 26500、Consumption (g per capita) in Switzerland (2009): 0.013、Consumption (g per capita、approx.) in Germany (2009): 0.092、exact) in Germany (2009): 0.12、Consumption (g per capita) in the USA (2002): 0.094、Excretion rate: 0.98、Calculated removal (%): 6.2、For use in the treatment of infections caused by susceptible strains of microorganisms in the following diseases: respiratory tract infections (upper and lower) of mild to moderate degree、pertussis (whooping cough)、as adjunct to antitoxin in infections due to <i>Corynebacterium diphtheriae<、i>、in the treatment of infections due to <i>Corynebacterium minutissimum<、intestinal amebiasis caused by <i>Entamoeba histolytica<、acute pelvic inflammatory disease caused by <i>Neisseria gonorrhoeae<、skin and soft tissue infections of mild to moderate severity caused by <i>Streptococcus pyogenes<、i> and <i>Staphylococcus aureus<、primary syphilis caused by <i>Treponema pallidum<、infections caused by <i>Chlamydia trachomatis<、nongonococcal urethritis caused by <i>Ureaplasma urealyticum<、and Legionnaires' disease caused by <i>Legionella pneumophila<、i>.、Use Classification: Animal Drugs -> FDA Approved Animal Drug Products (Green Book) -> Active Ingredients、Veterinary Drug -> ANTIMICROBIAL_AGENT -> JECFA Functional Classes、Pharmaceuticals -> Animal Drugs -> Approved in Taiwan、Methods of Manufacturing: Elaborated during the growth of a strain of Streptomycees erythreus.、Formulations、Preparations: Table: Erythromycin Lactobionate Preparations [Table#4384]、Table: Erythromycin Preparations [Table#4385]、Table: Erythromycin Ethylsuccinate Preparations [Table#4386]、Table: Erythromycin Stearate Preparations [Table#4387]、For more Formulations、Preparations (Complete) data for Erythromycin (6 total)、please visit the HSDB record page.、U.S. Production: approx 1800 metric tons (1979) (estimate)、General Manufacturing Information: Isolation: McGuire et al、Antibiot & Chemother 2、281 (1952)、Bunch、McGuire、US Patent 2、653、899 (1953 to Lilly)、Clark、Jr、823、203 (1958 to Abbott).、There are three major erythromycins produced during fermentation、designated A、B、and C、A is the major and most important component.、Antibiotic substance produced by strain of Streptomyces erythreus (Waksman) Waksman & Henrici、found in soil sample from Philippine Archipelago.、... belongs to the macrolide group of antibiotics |
登记用途：Uses: Antibiotic、THERAPEUTIC CATEGORY: Antibacterial、Erythromycin stearate、THERAPEUTIC CATEGORY (VETERINARY): Antibacterial、MEDICATION、Use (kg) in Switzerland (2009): >100、Use (kg、approx.) in Germany (2009): >7500、exact) in Germany (2009): 9435、Use (kg) in USA (2002): 26500、Consumption (g per capita) in Switzerland (2009): 0.013、Consumption (g per capita、approx.) in Germany (2009): 0.092、exact) in Germany (2009): 0.12、Consumption (g per capita) in the USA (2002): 0.094、Excretion rate: 0.98、Calculated removal (%): 6.2、For use in the treatment of infections caused by susceptible strains of microorganisms in the following diseases: respiratory tract infections (upper and lower) of mild to moderate degree、pertussis (whooping cough)、as adjunct to antitoxin in infections due to <i>Corynebacterium diphtheriae<、i>、in the treatment of infections due to <i>Corynebacterium minutissimum<、intestinal amebiasis caused by <i>Entamoeba histolytica<、acute pelvic inflammatory disease caused by <i>Neisseria gonorrhoeae<、skin and soft tissue infections of mild to moderate severity caused by <i>Streptococcus pyogenes<、i> and <i>Staphylococcus aureus<、primary syphilis caused by <i>Treponema pallidum<、infections caused by <i>Chlamydia trachomatis<、nongonococcal urethritis caused by <i>Ureaplasma urealyticum<、and Legionnaires' disease caused by <i>Legionella pneumophila<、i>.、Use Classification: Animal Drugs -> FDA Approved Animal Drug Products (Green Book) -> Active Ingredients、Veterinary Drug -> ANTIMICROBIAL_AGENT -> JECFA Functional Classes、Pharmaceuticals -> Animal Drugs -> Approved in Taiwan、Methods of Manufacturing: Elaborated during the growth of a strain of Streptomycees erythreus.、Formulations、Preparations: Table: Erythromycin Lactobionate Preparations [Table#4384]、Table: Erythromycin Preparations [Table#4385]、Table: Erythromycin Ethylsuccinate Preparations [Table#4386]、Table: Erythromycin Stearate Preparations [Table#4387]、For more Formulations、Preparations (Complete) data for Erythromycin (6 total)、please visit the HSDB record page.、U.S. Production: approx 1800 metric tons (1979) (estimate)、General Manufacturing Information: Isolation: McGuire et al、Antibiot & Chemother 2、281 (1952)、Bunch、McGuire、US Patent 2、653、899 (1953 to Lilly)、Clark、Jr、823、203 (1958 to Abbott).、There are three major erythromycins produced during fermentation、designated A、B、and C、A is the major and most important component.、Antibiotic substance produced by strain of Streptomyces erythreus (Waksman) Waksman & Henrici、found in soil sample from Philippine Archipelago.、... belongs to the macrolide group of antibiotics。
红霉素，[N-甲基-14C] 是一种化工化合物，登记 CAS 号为 82343-12-2，分子式 C37H67NO13（分子量 733.9）。
登记 CAS 号：82343-12-2
其分子式 C37H67NO13 由 37 个碳、67 个氢、1 个氮、13 个氧 组成。
别名/同义词：红霉素，[N-甲基-14C] · ERYTHROMYCIN, [N-METHYL-14C]
红霉素，[N-甲基-14C] 的 CAS 登记号为 82343-12-2。
分子式 C37H67NO13，分子量 733.9。
别名/同义词：红霉素，[N-甲基-14C]、ERYTHROMYCIN, [N-METHYL-14C]。
登记用途：Uses: Antibiotic、THERAPEUTIC CATEGORY: Antibacterial、Erythromycin stearate、THERAPEUTIC CATEGORY (VETERINARY): Antibacterial、MEDICATION、Use (kg) in Switzerland (2009): >100、Use (kg、approx.) in Germany (2009): >7500、exact) in Germany (2009): 9435、Use (kg) in USA (2002): 26500、Consumption (g per capita) in Switzerland (2009): 0.013、Consumption (g per capita、approx.) in Germany (2009): 0.092、exact) in Germany (2009): 0.12、Consumption (g per capita) in the USA (2002): 0.094、Excretion rate: 0.98、Calculated removal (%): 6.2、For use in the treatment of infections caused by susceptible strains of microorganisms in the following diseases: respiratory tract infections (upper and lower) of mild to moderate degree、pertussis (whooping cough)、as adjunct to antitoxin in infections due to <i>Corynebacterium diphtheriae<、i>、in the treatment of infections due to <i>Corynebacterium minutissimum<、intestinal amebiasis caused by <i>Entamoeba histolytica<、acute pelvic inflammatory disease caused by <i>Neisseria gonorrhoeae<、skin and soft tissue infections of mild to moderate severity caused by <i>Streptococcus pyogenes<、i> and <i>Staphylococcus aureus<、primary syphilis caused by <i>Treponema pallidum<、infections caused by <i>Chlamydia trachomatis<、nongonococcal urethritis caused by <i>Ureaplasma urealyticum<、and Legionnaires' disease caused by <i>Legionella pneumophila<、i>.、Use Classification: Animal Drugs -> FDA Approved Animal Drug Products (Green Book) -> Active Ingredients、Veterinary Drug -> ANTIMICROBIAL_AGENT -> JECFA Functional Classes、Pharmaceuticals -> Animal Drugs -> Approved in Taiwan、Methods of Manufacturing: Elaborated during the growth of a strain of Streptomycees erythreus.、Formulations、Preparations: Table: Erythromycin Lactobionate Preparations [Table#4384]、Table: Erythromycin Preparations [Table#4385]、Table: Erythromycin Ethylsuccinate Preparations [Table#4386]、Table: Erythromycin Stearate Preparations [Table#4387]、For more Formulations、Preparations (Complete) data for Erythromycin (6 total)、please visit the HSDB record page.、U.S. Production: approx 1800 metric tons (1979) (estimate)、General Manufacturing Information: Isolation: McGuire et al、Antibiot & Chemother 2、281 (1952)、Bunch、McGuire、US Patent 2、653、899 (1953 to Lilly)、Clark、Jr、823、203 (1958 to Abbott).、There are three major erythromycins produced during fermentation、designated A、B、and C、A is the major and most important component.、Antibiotic substance produced by strain of Streptomyces erythreus (Waksman) Waksman & Henrici、found in soil sample from Philippine Archipelago.、... belongs to the macrolide group of antibiotics。
红霉素，[N-甲基-14C]（CAS 82343-12-2）的独立参考数据，整理自公开化学数据库。
| CAS 号 | 82343-12-2 |
|---|---|
| PubChem CID | 12560 |
| 分子式 | C37H67NO13 |
| IUPAC 名称 | (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione |
| UNII（FDA） | 63937KV33D |
| Molecular Weight | 733.9 |
|---|---|
| XLogP3 | 2.7 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 7 |
| Exact Mass | 733.46124119 |
| Monoisotopic Mass | 733.46124119 |
| Topological Polar Surface Area | 194 |
| Heavy Atom Count | 51 |
| Boiling Point | 719.69 |
|---|---|
| Melting Point | 133-135 |
| Melting Point | 191 °C |
| Solubility | 4.59e-01 g/L |
| LogP | 2.6 |
| LogP | log Kow = 3.06 |
| LogP | 3.06 |
| Ionization Efficiency | 4.85 |
| Ionization Efficiency | 2.7 |
| Ionization Efficiency | MeCN (80%) |
erythromycin; 114-07-8; Erythromycin A; E-Mycin; Abomacetin; Ilotycin; Emgel; Erymax; Eritromicina; Erythromycine; Erythromycinum; Robimycin; Torlamicina; Eryderm; Erythromycin base; Erycette
| 法规与食品接触 | ANTIMICROBIAL_AGENT: Veterinary Drug 0-0.7 µg/kg bw TRS 939-JECFA 66/33 FAS 57-JECFA66/31 |
|---|---|
| GHS 通报统计 | 34.2% (66 / 193) |
| GHS 通报统计 | 34.2% (66 / 193) |
|---|---|
| 已通报的危害声明 | H317 (18.7%), H319 (32.6%), H334 (18.1%), H400 (14.5%), H410 (14.5%) |
红霉素，[N-甲基-14C] · CAS 82343-12-2 · C37H67NO13. UNII 63937KV33D. Boiling Point: 719.69; Melting Point: 133-135; Melting Point: 191 °C.
数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。
English page: ERYTHROMYCIN, [N-METHYL-14C]